As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of ORIC Pharmaceuticals, Inc. The largest reported stake is Nextech Crossover I GP S.a. r.l.'s, at 8.4%. 14 filings are on record since July 17, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like ORIC Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: T. Rowe Price Associates, Inc. · Percent: 5.4% · SCHEDULE 13G
- · Holder: Viking Global Investors LP · Percent: 7.8% · SCHEDULE 13G/A
- · Holder: Point72 Asset Management, L.P. · Percent: 0% · SCHEDULE 13G/A
- · Holder: Venrock Healthcare Capital Partners III, L.P. · Percent: 4.2% · SCHEDULE 13G/A
- · Holder: Pfizer Inc. (IRS Identification No.: 13-5315170) · Percent: 3.3% · SCHEDULE 13G/A
ORIC Pharmaceuticals, Inc. has 14 Schedule 13D or 13G filings on record since 2025-07-17. 5 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Nextech Crossover I GP S.a. r.l. | 8.4% | 7,162,637 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Viking Global Investors LP | 7.8% | 8,264,607 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| EcoR1 Capital, LLC | 6.9% | 6,728,116 | SCHEDULE 13G, 2025-08-05 | 2025-07-29 |
| BlackRock, Inc. | 5.6% | 5,473,145 | SCHEDULE 13G, 2026-01-21 | 2025-12-31 |
| T. Rowe Price Associates, Inc. | 5.4% | 5,387,783 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| SR One Capital Management, LLC | 4.75% | 4,615,384 | SCHEDULE 13D/A, 2025-08-14 | 2025-08-12 |
| Alkeon Capital Management LLC | 4.6% | 4,504,096 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | 4,319,765 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| 3.7% | 3,627,493 | SCHEDULE 13G/A, 2025-11-17 | 2025-09-30 | |
| Pfizer Inc. (IRS Identification No.: 13-5315170) | 3.3% | 3,442,940 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind ORIC Pharmaceuticals, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on ORIC Pharmaceuticals, Inc. and the records around it.
ORIC Pharmaceuticals, Inc. elsewhere on the record
- Form D filing Jun 2025
- Who owns it
Companies that share a holder
- Alkeon Capital Management LLC also filed stake reports on 1 other company: Hinge Health, Inc. (Feb 2026)
- Nextech Crossover I GP S.a. r.l. also filed stake reports on 2 other companies: Tango Therapeutics, Inc. (Aug 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), Allogene Therapeutics, Inc. (Feb 2026), NEXTCURE, INC. (Feb 2026)
Watch ORIC Pharmaceuticals, Inc.
Get an email when ORIC Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ORIC Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ORIC Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ORIC Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
SR One Capital Management, LLC
Not applicable.Item 4 of the SCHEDULE 13D/A filed 2025-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 4.2% | SCHEDULE 13G/A |
| 2025-08-05 | EcoR1 Capital, LLC | 6.9% | SCHEDULE 13G |
| 2025-08-14 | Viking Global Investors LP | 9.99% | SCHEDULE 13G/A |
| 2025-08-14 | SR One Capital Management, LLC | 4.75% | SCHEDULE 13D/A |
| 2025-08-14 | Nextech Crossover I GP S.a. r.l. | 8.4% | SCHEDULE 13G/A |
| 2025-11-13 | Alkeon Capital Management LLC | 4.6% | SCHEDULE 13G/A |
| 2025-11-17 | David V Goeddel | 3.7% | SCHEDULE 13G/A |
| 2026-01-21 | BlackRock, Inc. | 5.6% | SCHEDULE 13G |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 5.8% | SCHEDULE 13G/A |
| 2026-05-12 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 3.3% | SCHEDULE 13G/A |
| 2026-05-15 | T. Rowe Price Associates, Inc. | 5.4% | SCHEDULE 13G |
| 2026-05-15 | Viking Global Investors LP | 7.8% | SCHEDULE 13G/A |
| 2026-05-15 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Venrock Healthcare Capital Partners III, L.P. | 4.2% | SCHEDULE 13G/A |
Questions about who owns ORIC Pharmaceuticals, Inc.
Who owns ORIC Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of ORIC Pharmaceuticals, Inc.: Nextech Crossover I GP S.a. r.l. (8.4%, Schedule 13G/A, filed 2025-08-14), Viking Global Investors LP (7.8%, Schedule 13G/A, filed 2026-05-15), EcoR1 Capital, LLC (6.9%, Schedule 13G, filed 2025-08-05), BlackRock, Inc. (5.6%, Schedule 13G, filed 2026-01-21) and T. Rowe Price Associates, Inc. (5.4%, Schedule 13G, filed 2026-05-15).
Who are the largest shareholders of ORIC Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of ORIC Pharmaceuticals, Inc. on this page are Nextech Crossover I GP S.a. r.l. (8.4%), Viking Global Investors LP (7.8%) and EcoR1 Capital, LLC (6.9%).
When did Nextech Crossover I GP S.a. r.l. buy into ORIC Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Nextech Crossover I GP S.a. r.l. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 8.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for ORIC Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 6, 2025 | Form D, private offering | $125M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for ORIC Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.